About biorestorative therapies inc. - BRTX
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.
BRTX At a Glance
BioRestorative Therapies, Inc.
40 Marcus Drive
Melville, New York 11747
| Phone | 1-631-760-8100 | Revenue | 359.70K | |
| Industry | Medical Specialties | Net Income | -14,241,975.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BRTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 29.377 |
| Price to Book Ratio | 30.428 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.503 |
| Enterprise Value to Sales | 21.604 |
| Total Debt to Enterprise Value | 0.018 |
BRTX Efficiency
| Revenue/Employee | 25,692.857 |
| Income Per Employee | -1,017,283.929 |
| Receivables Turnover | 23.206 |
| Total Asset Turnover | 0.044 |
BRTX Liquidity
| Current Ratio | 0.84 |
| Quick Ratio | 0.84 |
| Cash Ratio | 0.793 |
BRTX Profitability
| Gross Margin | 34.993 |
| Operating Margin | -4,350.05 |
| Pretax Margin | -3,959.404 |
| Net Margin | -3,959.404 |
| Return on Assets | -174.113 |
| Return on Equity | -320.472 |
| Return on Total Capital | -2,849.438 |
| Return on Invested Capital | -320.472 |
BRTX Capital Structure
| Total Debt to Total Equity | 40.105 |
| Total Debt to Total Capital | 28.625 |
| Total Debt to Total Assets | 3.507 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |